



Press Release

Wednesday, February 25, 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE : 532531
NSE : STAR

FY 2008 revenues up 49% to Rs.1,136 crores (USD 260 mio)

**Operating EBITDA at Rs.186 crores (USD 43 mio)
against negative operating EBITDA in 2007**

**PAT at Rs.108 crores (USD 25 mio)
against negative PAT in 2007**

EPS (diluted) at Rs.24.70 (USD 0.56 per share)

Source : Company Financials, IGAAP Consolidated

Strides Arcolab Limited, today announced revenue of INR 1,136 Crores for the year ended December 31, 2008, a 49% increase over the same period of the prior year.

Highlights

- Record revenue and profits since inception of company
- 15 ANDA / NDA approvals in 2008
- 51 pending ANDA / NDA in 2008
- Strong pipeline growth continues. Guides in excess of 40 filings in 2009.
- 16 successful global regulatory plant inspections including USFDA, MHRA, TGA, WHO, ANVISA in year 2008
- Successful integration of Ascent Pharmahealth – ASX listed Australasian Pharma Company (current holding 55.46%)
- Transformational product licensing deal announced with GSK for 95 countries (in partnership with JV partner Aspen)
- Global management team in place.
- AS 30 adoption and IFRS convergence in 2009

Strides Arcolab's Vice Chairman & Group CEO Mr. Arun Kumar commented

"The Year 2008 is a transformational year for Strides with operation revenues surpassing the key milestone of Rs.1000 Crores, closing at Rs.1136 crores representing a 49% growth over the previous year and a significant growth in



EBITDA and profits. A clearly defined strategy is being executed worldwide to deliver sustained and profitable growth in the years ahead.

Arun Kumar continued, "2008 saw another key milestone in R&D revenues for the year exceeding Rs.100 crores, in less than four years since we commenced R&D at Strides. We have broadened our portfolio to niche and highly specialized areas, entered into significant licensing transactions and have completed growth investments in new capex mainly in Steriles which will go commercial in H2 2009."


See Attachments For

- Revenue break up – Annexure 1 a & b
- Exceptional items explanatory notes – Annexure 2
- Geographical distribution of sales – Annexure 3

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.



Additional information is available at the company's website at www.stridesarco.com

For further information, please contact

Mr. Arun Kumar, Group CEO Tel: +91-80-6658 0118	Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 9880376648 Email: maheshn@corvoshandwick.co.in
Mr. T.S. Rangan, Group CFO Tel: +91 80 6658 0115	Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: +91 9916728393 Email: kasturi@corvoshandwick.co.in

